1. Home
  2. STVN vs DNTH Comparison

STVN vs DNTH Comparison

Compare STVN & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stevanato Group S.p.A.

STVN

Stevanato Group S.p.A.

HOLD

Current Price

$21.38

Market Cap

5.7B

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$90.71

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STVN
DNTH
Founded
1949
2015
Country
Italy
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
5.9B
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
STVN
DNTH
Price
$21.38
$90.71
Analyst Decision
Buy
Strong Buy
Analyst Count
3
13
Target Price
$25.67
★ $121.00
AVG Volume (30 Days)
315.2K
★ 625.5K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
★ 0.39%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $2,036,000.00
Revenue This Year
$9.67
N/A
Revenue Next Year
$9.99
$29.48
P/E Ratio
$27.15
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$12.89
$32.28
52 Week High
$27.99
$117.88

Technical Indicators

Market Signals
Indicator
STVN
DNTH
Relative Strength Index (RSI) 52.04 33.61
Support Level $20.17 $89.21
Resistance Level $22.00 $97.60
Average True Range (ATR) 0.87 4.99
MACD -0.01 -1.44
Stochastic Oscillator 50.09 18.61

Price Performance

Historical Comparison
STVN
DNTH

About STVN Stevanato Group S.p.A.

Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Share on Social Networks: